glutathione injection process Injections: Side Effects & Benefits How to Self-Administer Subcutaneous &

Cytom Chapter 9, Unit 9.11 (2004)

As a whole, SAMHSA'S regulatory changes largely reflect significant changes in evidence-based practice and towards patient-centered care in the treatment of OUD that have occurred in the past couple of decades, including considerations of the need to address unmet health related social needs (HRSN) that impose barriers on a patient's ability to initiate, engage, and remain in treatment, including in areas of education, employment, and housing as well as in harm reduction strategies that decrease the negative consequences associated with a patient's use or abuse of opioids, and recovery support services that address the chronic nature of OUD and the need for supports across the full continuum of care

Following the second dose, the incidence decreases to about 23 per million post-second dose [99,185]

Transparent labeling: research-use only, no medical claims